Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial-Reference-Cited by-同舟云学术

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial

Published:2014-04 Issue:4 Volume:167 Page:437-444.e5
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Bonaca Marc P.,Bhatt Deepak L.,Braunwald Eugene,Cohen Marc,Steg Philippe Gabriel,Storey Robert F.,Held Peter,Jensen Eva C.,Sabatine Marc S.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference43 articles.

1. Platelet activation and atherothrombosis;Kapoor;N Engl J Med,2008

2. Role of platelets in atherothrombosis;Jennings;Am J Cardiol,2009

3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients;BMJ,2002

4. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials;Baigent;Lancet,2009

5. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation;Yusuf;N Engl J Med,2001

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial;European Heart Journal - Cardiovascular Pharmacotherapy;2024-07-18

2. An Overview of Clinical Trials on the Duration of Dual Antiplatelet Therapy and the Scope of Novel Oral Anticoagulants Following Percutaneous Coronary Intervention;Journal of Clinical and Preventive Cardiology;2024-01

3. The search for the perfect antiplatelet treatment continues;European Heart Journal - Cardiovascular Pharmacotherapy;2023-12

4. Pathophysiological and Molecular Basis of the Side Effects of Ticagrelor: Lessons from a Case Report;International Journal of Molecular Sciences;2023-06-29

5. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes;Vascular Pharmacology;2023-04